Sujet(s)
Anatoxine diphtérique/effets indésirables , Vaccin diphtérie-tétanos-coqueluche/effets indésirables , Hyperleucocytose/étiologie , Anatoxine tétanique/effets indésirables , Glycémie/métabolisme , Enfant d'âge préscolaire , Vaccin antidiphtérique antitétanique , Association médicamenteuse , Humains , Hydrocortisone/sang , Insuline/sangRÉSUMÉ
Many adverse clinical events occur after pertussis immunization in children, but the pathophysiology is not well understood. It has been suggested that some of these adverse events may be due to biologically-active LPF and endotoxin present in DTP vaccines. Fifty-six children were studied who experienced severe reactions (fever greater than or equal to 40.5 degrees C, seizures, persistent crying greater than or equal to 3 hours or hypotonic-hyporesponsive episodes) within 48 hr of DTP immunization. Leukocytosis with neutrophilia was noted acutely (after vaccination) compared to follow-up (approximately one month later). No changes in insulin or glucose values were noted. Utilizing the CHO cell assay, no biologically-active LPF was found in the acute sera of children who had DTP-associated seizures. We found no evidence that biologically-active LPF or altered insulin/glucose metabolism were related to severe DTP-associated reactions.
Sujet(s)
Vaccin anticoquelucheux/effets indésirables , Glycémie/métabolisme , Cris , Fièvre/étiologie , Humains , Nourrisson , Insuline/sang , Hyperleucocytose/étiologie , Hypotonie musculaire/étiologie , Toxine pertussique , Vaccin anticoquelucheux/analyse , Crises épileptiques/étiologie , Facteurs de virulence des Bordetella/sangRÉSUMÉ
The purpose of this study was to evaluate differences in the safety and immunogenicity of Haemophilus influenzae type b (Hib) capsular polysaccharide vaccine produced by two manufacturers (Connaught and Praxis) in children 18 and 24 months of age. Eighty-five children were evaluated in a prospective, double-blind, randomized fashion. Postvaccination antibody concentrations (measured by radioimmunoassay) and response rates were not significantly different between the two manufacturers' vaccines but immunogenicity was significantly less in 18-month-old children (antibody concentration, 0.149 microgram/ml) compared with 24-month-old children (0.838 microgram/ml) (P = 0.001). No significant differences were noted in the safety of the two vaccines. This study suggests that previously observed differences of immunogenicity data between various type b capsular polysaccharide vaccines are due to differences in antibody assays, not in vaccines. Eighteen-month-old children appear to have a relatively poor immune response to type b capsular polysaccharide. Therefore to optimize the benefits of immunization, we suggest children receive this vaccine at 24 months of age.
